These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8698676)

  • 41. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro.
    Störmer E; Brockmöller J; Roots I; Schmider J
    Psychopharmacology (Berl); 2000 Sep; 151(4):312-20. PubMed ID: 11026737
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro effects of tacrolimus on human cytochrome P450.
    Lecointre K; Furlan V; Taburet AM
    Fundam Clin Pharmacol; 2002 Dec; 16(6):455-60. PubMed ID: 12685503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
    Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
    Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
    Hemeryck A; Belpaire FM
    Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
    Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
    Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study.
    Gram LF; Guentert TW; Grange S; Vistisen K; Brøsen K
    Clin Pharmacol Ther; 1995 Jun; 57(6):670-7. PubMed ID: 7781267
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM; Verhoeven CH; Shimada T; Back DJ
    J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
    Rasmussen BB; Nielsen TL; Brøsen K
    Eur J Clin Pharmacol; 1998; 54(9-10):735-40. PubMed ID: 9923577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
    Bu HZ; Magis L; Knuth K; Teitelbaum P
    Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes.
    Xu ZH; Wang W; Zhao XJ; Huang SL; Zhu B; He N; Shu Y; Liu ZQ; Zhou HH
    Br J Clin Pharmacol; 1999 Sep; 48(3):416-23. PubMed ID: 10510155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.
    Greenblatt DJ; von Moltke LL; Schmider J; Harmatz JS; Shader RI
    J Clin Pharmacol; 1996 Sep; 36(9):792-8. PubMed ID: 8889899
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of sertraline on protein binding of warfarin.
    Apseloff G; Wilner KD; Gerber N; Tremaine LM
    Clin Pharmacokinet; 1997; 32 Suppl 1():37-42. PubMed ID: 9068934
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.
    Lane RM
    Int Clin Psychopharmacol; 1996 Dec; 11 Suppl 5():31-61. PubMed ID: 9032002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
    Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
    Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
    Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
    J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples.
    Boobis AR; McKillop D; Robinson DT; Adams DA; McCormick DJ
    Xenobiotica; 1998 May; 28(5):493-506. PubMed ID: 9622851
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
    Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
    Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.